Melatonin does not reduce delirium severity in hospitalized older adults: Results of a randomized placebo-controlled trial

Peter W. Lange*, Alisa Turbić, Cheng Hwee Soh, Daniel Clayton-Chubb, Wen Kwang Lim, Rachel Conyers, Rosie Watson, Andrea B. Maier

*Corresponding author for this work

Research output: Contribution to JournalArticleAcademicpeer-review

Abstract

Background: Delirium is common in older inpatients, causing distress, cognitive decline, and death. Current therapies are unsatisfactory, limited by lack of efficacy and adverse effects. There is an urgent need for effective delirium treatment. Sleep wake cycle is disturbed in delirium; endogenous Melatonin is perturbed, and exogenous Melatonin is a safe and effective medication for sleep disorders. This study aims to determine the effect of oral Melatonin 5 mg immediate release (IR) nightly for five nights on the severity of delirium in older (≥65 years) medical inpatients. Methods: This was a double-blinded, randomized controlled trial in general internal medicine units of a tertiary teaching hospital. Older inpatients with Confusion Assessment Method positive, hyperactive or mixed delirium within 48 h of admission or onset of in-hospital delirium were included. The primary outcome was change in delirium severity measured with the Memorial Delirium Assessment Scale (MDAS). A previous pilot trial showed 120 participants randomized 1:1 to Melatonin or Placebo would provide 90% power to demonstrate a 3-point reduction in the MDAS. Results: One hundred and twenty participants were randomized, 61 to Melatonin 5 mg and 59 to Placebo. The medication was well tolerated. The mean MDAS improvement was 4.9 (SD 7.6) in the Melatonin group and 5.4 (SD 7.2) in the Placebo group, p-value 0.42, a non-significant difference. A post-hoc analysis showed length of stay (LOS) was shorter in the intervention group (median 9 days [Interquartile Range (IQR) 4, 12] vs. Placebo group 10 [IQR 6, 16] p-value = 0.033, Wilcoxon Rank Sum test). Conclusions: This trial does not support the hypothesis that Melatonin reduces the severity of delirium. This may be due to no effect of Melatonin, a smaller effect than anticipated, an effect not captured on a multidimensional delirium assessment scale, or a type II statistical error. Melatonin may improve LOS; this hypothesis should be studied.

Original languageEnglish
Pages (from-to)1802-1809
Number of pages8
JournalJournal of the American Geriatrics Society
Volume72
Issue number6
Early online date4 Mar 2024
DOIs
Publication statusPublished - Jun 2024

Bibliographical note

Publisher Copyright:
© 2024 The Authors. Journal of the American Geriatrics Society published by Wiley Periodicals LLC on behalf of The American Geriatrics Society.

Funding

Role of the Sponsor: The study was sponsored by the Royal Melbourne Hospital, which had no role in the design, methods, subject recruitment, data collections, analysis and preparation of paper. Open access publishing facilitated by The University of Melbourne, as part of the Wiley - The University of Melbourne agreement via the Council of Australian University Librarians.

FundersFunder number
Royal Melbourne Hospital
University of Melbourne
Australian University Librarians

    Keywords

    • aged neurocognitive disorders
    • delirium
    • inpatients
    • melatonin
    • sepsis-associated encephalopathy
    • sleep wake disorders

    Fingerprint

    Dive into the research topics of 'Melatonin does not reduce delirium severity in hospitalized older adults: Results of a randomized placebo-controlled trial'. Together they form a unique fingerprint.

    Cite this